REG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
21/04/2022 09:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220421:nRSU8787Ia&default-theme=true
RNS Number : 8787I Hutchmed (China) Limited 21 April 2022
Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Thursday, April 21, 2022:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards
granted under the Long Term Incentive Plan ("LTIP") on April 20, 2020 to the
following persons discharging managerial responsibilities were vested on April
20, 2022:-
Award Holder Number of American depositary shares ("ADS")
Mr Simon To (Executive Director) 2,397(1)
Dr Dan Eldar (Non-executive Director ("NED")) 2,397
Ms Edith Shih (NED) 2,397(2)
Mr Paul Carter (Independent Non-executive Director ("INED")) 2,037(3)
Dr Karen Ferrante (INED) 2,397
Mr Graeme Jack (INED) 2,397
Professor Tony Mok (INED) 2,397
Notes:
(1) Similar to the arrangement for his Director's fees, these ADSs
were not received by Mr Simon To, but were received by or for the account of
his employer, Hutchison Whampoa (China) Limited.
(2) Similar to the arrangement for her Director's fees, these ADSs were
not received by Ms Edith Shih, but were received by or for the account of her
employer, Hutchison International Limited.
(3) Mr Paul Carter elected, on acceptance of the grant of his awards, to
have 15% of his LTIP awards (amounting to US$7,500 with respect to his awards
which vested on April 20, 2022) held on his behalf by the trustee
administering the LTIP pending vesting in the form of cash, to settle his tax
liabilities in respect of his awards.
The notifications set out below are provided in accordance with the
requirements of the UK Market Abuse Regulation.
(a) Dr Dan Eldar
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Dr Dan Eldar
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US$0.10
Identification code
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 2,397 ADS
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2022-04-20
f)
Place of the transaction
Outside a trading venue
(b) Mr Paul Carter
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Mr Paul Carter
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US$0.10
Identification code
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 2,037 ADS
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2022-04-20
f)
Place of the transaction
Outside a trading venue
(c) Dr Karen Ferrante
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Dr Karen Ferrante
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US$0.10
Identification code
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 2,397 ADS
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2022-04-20
f)
Place of the transaction
Outside a trading venue
(d) Mr Graeme Jack
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Mr Graeme Jack
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US$0.10
Identification code
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 2,397 ADS
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2022-04-20
f)
Place of the transaction
Outside a trading venue
(e) Professor Tony Mok
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Professor Tony Mok
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US$0.10
Identification code
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 2,397 ADS
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2022-04-20
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2022-04-20
f)
Place of the transaction
Outside a trading venue
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has more than 4,600
personnel across all its companies, at the center of which is a team of about
1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug
candidates from in-house discovery into clinical studies around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, +1 (917) 570 7340 (Mobile)
Solebury Trout bmiles@troutgroup.com (mailto:bmiles@troutgroup.com)
Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
FTI Consulting +44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com (mailto:HUTCHMED@fticonsulting.com)
Asia - Zhou Yi, +852 9783 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com (mailto:HUTCHMED@brunswickgroup.com)
Nominated Advisor
Atholl Tweedie / Freddy Crossley, +44 (20) 7886 2500
Panmure Gordon (UK) Limited
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGLGDSXSDDGDBRecent news on HUTCHMED (China)
See all newsREG - Hutchmed China Ltd - Vesting of Awards Under the LTIP
AnnouncementREG - Hutchmed China Ltd - 2023 Annual Report and Notice of AGM
AnnouncementRCS - Hutchmed China Ltd - Data to be Presented at AACR Congress 2024
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance
AnnouncementRCS - Hutchmed China Ltd - Savolitinib sNDA Accepted in China
Announcement